NYU College of MedicineUnder the contract.

BG Medication enters into advancement and commercialization contract with Abbott Laboratories BG Medication, Inc. Galectin-3 is a novel biomarker that could are likely involved in detecting the progression and development of center failure http://silagracipla.net/contact . Ladapo, NYU College of MedicineUnder the contract, Abbott will lead to the advancement of the test relative to certain milestones and programs, and BG Medication and Abbott will collaborate to get regulatory filings and research to support the scientific utility of galectin-3 in the management of sufferers with acute decompensated center failure.D., President and CEO of BG Medication.S.